Venture Capital Shifts to Life Sciences
By Tim Busbey
Tim Busbey is a business and technology journalist from Ohio, who brings diverse writing experience to the Cronicle team. He works on our Cronicle tech and business blog and with our Cronicle content marketing clients.
Venture Capital Shift: From Software to Life Sciences
The venture capital landscape is a constantly shifting terrain, sensitive to market trends, emerging industries, and societal needs. In recent years, an interesting trend has emerged that defies conventional wisdom: venture capitalists are increasingly directing their funds toward life sciences over software startups. This shift is not only fascinating but also important to scrutinize, as it could have far-reaching implications for both industries and society as a whole. Let’s take a look at the history of venture capital investment and what this shift may mean.
Historical Context: VC Investment in Software
Historically, venture capitalists have been keen on investing in software startups. And why wouldn't they be? Software companies have several appealing attributes. First, they usually require relatively low initial capital to get off the ground compared to traditional businesses. Second, their scalability is virtually limitless; a software solution can be distributed to an infinite number of users without a corresponding increase in costs. Lastly, high return on investment (ROI) has always been a luring factor. Companies like Facebook, Uber, and Airbnb have offered phenomenal returns to their early investors, validating the focus on software.
The numbers don't lie. Billions of dollars have flowed into software companies over the past two decades. Software startups dominated the charts when it came to the number of deals made and the total amount of capital deployed. It seemed like software was the undisputed champion of venture capital attention.
However, as the saying goes, "change is the only constant," and the world of venture capital is no exception. There has been a noticeable pivot away from software, towards an industry that has been around for centuries yet is now seen as a ripe ground for disruption: life sciences.
The Pivot Towards Life Sciences
The realm of life sciences has increasingly caught the eye of venture capitalists, and for good reason. The first factor contributing to this change is market opportunity. As society becomes more health-conscious and the global population ages, the demand for innovative healthcare solutions is skyrocketing. The COVID-19 pandemic also highlighted the critical need for advancements in medical science, not just as a societal good, but also as a robust investment arena.
Secondly, technological advancements have reached a point where biology and tech are more interconnected than ever. Technologies such as CRISPR for gene editing, advancements in artificial intelligence for drug discovery, and the proliferation of wearable tech for health monitoring are creating new avenues for innovation and investment.
Thirdly, the promise of high returns exists in life sciences as well. While life science firms may require a more substantial initial investment and face a longer pathway to profitability due to regulatory hurdles, the potential for a massive payoff is real. Drugs, treatments, or technologies that address widespread medical issues can command high market prices and achieve significant scale.
Data corroborates this trend: investment in life sciences startups has been on a steady rise, both in terms of deal numbers and capital deployed, even overtaking software in certain metrics. According to a report from Silicon Valley Bank, the life sciences sector saw a 35.5% increase in 2021. In 2022, Tech Coast Angels, one of the most active angel groups in the U.S., reported that 54% of the startups they invested in were life sciences, which includes pharmaceuticals, medical diagnostics, medical devices, and digital health, while software accounted for just 22% of deals.
It's clear that life sciences have moved from the periphery to the core of venture capital focus.
To better understand this pivot, let's look at a couple of life sciences startups that have attracted significant venture capital investment.
Moderna, Inc. - Initially a relatively unknown biotech firm, Moderna became a household name due to its COVID-19 vaccine. Venture capital backing enabled the company to accelerate its mRNA technology, culminating in a vaccine developed in record time. The result? A market valuation in the tens of billions and a textbook case of a successful life sciences investment.
23andMe - This genetics testing company ventured into drug development using the genetic data collected from its consumer ancestry tests. With a unique business model and immense potential for personalized medicine, 23andMe has successfully secured hundreds of millions in venture capital funding.
Tempus - Focusing on data-driven precision medicine, Tempus has brought AI into the oncology field. They've attracted significant investment for their platform, which uses machine learning to analyze clinical data to assist in personalized treatment plans for cancer patients.
Crispr Therapeutics - A pioneer in gene editing, Crispr Therapeutics aims to develop transformative gene-based medicines for serious diseases. Their revolutionary approach to medical science has not only won them accolades but also substantial financial backing from VCs.
These examples are a testament to the shift in venture capital priorities. Life science startups are addressing crucial issues, pushing technological boundaries, and offering potentially huge returns on investment, thereby attracting significant venture capital attention.
Comparison: Life Sciences vs. Software
While both life sciences and software offer intriguing opportunities for venture capital, a closer look reveals some contrasting characteristics that are influencing investment decisions.
Investing in life sciences often involves a unique set of risks compared to software. Regulatory challenges, ethical considerations, and longer development cycles are just a few of the obstacles. However, the payoff can be massive if a company makes a significant medical breakthrough.
Software companies can iterate and update products quickly, often in a matter of weeks or even days. Life sciences, on the other hand, have a much longer innovation cycle, primarily due to rigorous testing and regulatory approvals. Nevertheless, once a product reaches the market, its impact can be transformative and enduring.
Software startups have generally shown quicker routes to profitability, given their scalable business models. Life sciences may involve more substantial initial investments and longer timelines but have the potential for considerable long-term gains.
Industry experts have increasingly advocated for life sciences as an investment avenue. Their support is often grounded in the industry's capacity to bring about meaningful change while also offering robust financial returns.
This shift in venture capital focus from software to life sciences has several significant implications:
For the VC Industry
Venture capitalists may need to adjust their expertise, due diligence methods, and investment timelines to fit the life sciences model.
For Life Sciences and Software
Increased investment can accelerate research and innovation in life sciences, potentially leading to groundbreaking discoveries. Conversely, reduced attention could compel software startups to seek alternative funding routes or adapt their business models for better appeal.
A focus on life sciences investment could lead to advancements in healthcare, medicine, and quality of life that would benefit society as a whole. On the flip side, less investment in software could slow the pace of digital innovation, although this area is less likely to experience a complete investment drought given its established importance.
Venture capital, known for its dynamic nature, has recently shown a marked preference for life sciences over the traditional darling, software. This pivot is significant for a variety of reasons: it alters the venture capital landscape, impacts the pace and direction of innovation, and has societal implications that extend beyond mere financial returns.
While it remains to be seen whether this trend is a transient shift or a long-term change, the current signs point to a future where life sciences will occupy a central role in venture capital portfolios. Both sectors—life sciences and software—undoubtedly have the power to shape our lives in different but substantial ways. They can even be combined, as life sciences startups often create wearable medical tech or behavioral health apps for end consumers. This investment shift, therefore, is not just a matter for venture capitalists or industry experts to ponder; it's a development that holds relevance for all of us, influencing how we live, how we manage our health, and how we interact with technology.